PDS Biotechnology Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that PDS Biotechnology Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.56M) | Mar 30, 2026 |
| FY2025 | Sep 30, 2025 | ($9.01M) | Mar 30, 2026 |
| FY2025 | Jun 30, 2025 | ($9.43M) | Mar 30, 2026 |
| FY2025 | Mar 31, 2025 | ($8.49M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($7.95M) | Mar 30, 2026 |
| FY2025 | Sep 30, 2024 | ($10.73M) | Mar 30, 2026 |
| FY2025 | Jun 30, 2024 | ($8.33M) | Mar 30, 2026 |
| FY2025 | Mar 31, 2024 | ($10.60M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($10.90M) | Mar 27, 2025 |
| FY2024 | Sep 30, 2023 | ($10.85M) | Mar 27, 2025 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($31.54M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($36.32M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($43.05M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($41.67M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($21.44M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($14.90M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($21.03M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | ($3.65M) | Mar 27, 2020 |
| FY2017 | Dec 31, 2017 | ($16.12M) | Mar 1, 2018 |
| FY2017 | Sep 30, 2017 | ($10.90M) | Mar 1, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.03M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $22.57M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $27.76M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $29.43M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $11.25M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $7.92M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $6.10M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $830.7K | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $34.31M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $24.83M | Mar 1, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($27.75M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($35.03M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($33.64M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($25.71M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($12.49M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($13.15M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($18.07M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | ($1.57M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($40.70M) | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | ($32.19M) | Mar 1, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $29.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 27, 2025 |
| FY2018 | Dec 31, 2018 | $0 | Feb 21, 2019 |
| FY2018 | Dec 31, 2017 | $188.7K | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $686.7K | Mar 1, 2018 |
| FY2017 | Dec 31, 2015 | $1.31M | Mar 1, 2018 |
| FY2016 | Dec 31, 2014 | $884.8K | Mar 2, 2017 |
| FY2015 | Dec 31, 2013 | $136.9K | Mar 8, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.49M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $45.36M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $59.39M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $77.01M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $67.20M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $30.89M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $14.49M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $164.4K | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $92.62M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $110.91M | Mar 1, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.24M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $26.35M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $33.26M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $33.01M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $3.99M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $3.76M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $2.79M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $2.23M | Mar 27, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.25M | Mar 30, 2026 |
| FY2025 | Sep 30, 2025 | $9.45M | Mar 30, 2026 |
| FY2025 | Jun 30, 2025 | $15.96M | Mar 30, 2026 |
| FY2025 | Mar 31, 2025 | $22.36M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $19.00M | Mar 30, 2026 |
| FY2025 | Sep 30, 2024 | $22.00M | Mar 30, 2026 |
| FY2025 | Jun 30, 2024 | $30.92M | Mar 30, 2026 |
| FY2025 | Mar 31, 2024 | $37.18M | Mar 30, 2026 |
| FY2025 | Dec 31, 2023 | $26.13M | Mar 30, 2026 |
| FY2024 | Sep 30, 2023 | $24.48M | Mar 27, 2025 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($216.61M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($182.11M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($144.50M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($101.56M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($60.70M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($43.79M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($28.94M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | ($21.94M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($151.95M) | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | ($101.07M) | Mar 1, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.71M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $41.69M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $56.56M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $73.82M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $65.24M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $28.84M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $12.16M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $103.7K | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $88.07M | Feb 21, 2019 |
| FY2018 | Dec 31, 2016 | $106.40M | Feb 21, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $5.47M | Mar 8, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 54.88M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 37.99M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 33.09M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 30.17M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 28.45M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | 22.26M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 5.28M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | 3.42M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | 30.87M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | 28.92M | Mar 1, 2018 |